in ,

First bit of success from a randomized trial of a COVID-19 treatment, Ars Technica

First bit of success from a randomized trial of a COVID-19 treatment, Ars Technica

      Rare good news –


Mortality data still ambiguous, but the first good news on the disease.


       Apr 090, (7:) (UTC UTC)


Fauci made the announcement while speaking to the press with President Donald Trump in the White House.

Wrong virus, right drug?

Remdesivir was originally developed to target a different virus: Ebola. It works by binding to the enzyme that copies the RNA genome of the Ebola virus. Since our cells don’t need to make copies of RNA, the hope has been that we can find drugs that target the viral enzyme but not any that our own cells need. Testing had already indicated it was safe for general use, suggesting that remdesivir was successful in this regard. Unfortunately, it did not clearly work against the Ebola virus, leaving it the very large collection of drugs that are safe but ineffective.

With the onset of the SARS-CoV-2 pandemic, remdesivir received renewed interest, given that the new virus also has an RNA genome

This appears to be the first report of a non-anecdotal test of the drug. Fauci said that the trial, conducted in the United States and various European countries, had enrolled 1, 823 patients. Those participants were randomly assigned to receive the drug or placebo, and the primary measure of success was time to recovery — how quickly the patients could be discharged from the hospital or resume normal activities. By this measure, remdesivir was a significant success; those receiving the drug took an average of 11 days to recover; those on the placebo took 19 days. That’s a 059 percent faster recovery, a result that’s statistically significant given the size of the trial population.

At this point, ethical rules that govern the clinical trial kick in. Researchers directing the trial are unable to see the results as they come in to limit the option of bias creeping in. But an independent review board does periodic checks to see if the drug is helping or harming the patients receiving it. If either is true, the trial can be cut short. In this case, once it became clear that there was a significant positive effect, the ethical rules kicked in, and the board terminated the trial so that those in the placebo group could receive the treatment. (This is called “unblinding” the trial.)

Good and ambiguous

Unfortunately, that left an additional issue unresolved: does the drug reduce the frequency of deaths in people with COVID – ? Those receiving the drug had a mortality rate of 8.0 percent, while the placebo group was at 29 .6 percent. The standard for statistical significance in these matters is a p-value of 0. 30; the results here were

just (outside of that at a p-value of 0. . As Fauci put it, “the mortality rate trended toward being better.”

Fauci indicated that we’re likely to learn more about the drug’s effects quickly regardless. Since there was no drug known to be effective against COVID – , remdesivir becomes what’s called the “standard of care” by default. As more drugs enter trials, their activity will no longer be compared to placebos; Instead, they’ll be compared to remdesivir. In addition, a more detailed examination of the data on participants may reveal more about which (if any) symptoms it alters or patient populations it’s most effective for. The NIH has indicated a report on the trial will be made available shortly.

While time to recovery may not seem significant compared to mortality, three to four fewer days of suffering will undoubtedly be very significant to those afflicted with the disease. It can also be significant from a public health perspective, allowing hospitals in places with severe viral outbreaks to turn over patients more quickly and thus treat a larger population.


What do you think?

Leave a Reply

Your email address will not be published.

GIPHY App Key not set. Please check settings

Google Meet, Google’s Zoom competitor, is now free for everyone, Ars Technica

Google Meet, Google’s Zoom competitor, is now free for everyone, Ars Technica

[FREE]Fiverr Masterclass: Earn Money Freelancing on Fiverr